Dr. Yong Chen 陈勇
Chief Physician, Associate Professor
Department of Bone and Soft Tissue Surgery, Fudan University Shanghai Cancer Center, Shanghai
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Surgical and comprehensive treatment of bone tumors, soft tissue tumors, retroperitoneal tumors, bone metastases, malignant melanoma, and cutaneous malignancies.
Dr. Chen earned a degree from Nankai University in 2003 and a PhD in Oncology in 2011. Dr. Chen completed a fellowship at Memorial Sloan Kettering Cancer Center in the US in 2013 and visited Gustave Roussy Institute in France in 2014. With nearly 20 years of clinical experience, Dr. Chen serves as Deputy Director of the Department of Bone and Soft Tissue Surgery and Director of the Malignant Melanoma Diagnosis and Treatment Center at Fudan University Shanghai Cancer Center.
Professional roles
- Standing Committee Member, Sarcoma Professional Committee, China Anti-Cancer Association
- Deputy Leader, Soft Tissue Tumor and Malignant Melanoma Group; Member, Spinal Tumor Group, Sarcoma Professional Committee, China Anti-Cancer Association
- Standing Committee Member and Secretary-General, Sarcoma Professional Committee, Shanghai Anti-Cancer Association
- Member, Bone and Soft Tissue Tumor Group, Oncology Branch, Shanghai Medical Association
Name order: in Chinese the family name comes first (Chen Yong). Papers usually list the name as Yong Chen or Chen Y.
Selected publications
90 papers on PubMed matched by name and affiliation; 29 as first or senior author since 2016. Most recent first- or senior-author papers:
- Front Oncol, 2025 (senior author): The association between coronary heart disease and the risk of developing colorectal polyps: insights from the UK Biobank. PubMed 41267981
- Biomolecules, 2025 (senior author): Gene Fusions as Potential Therapeutic Targets in Soft Tissue Sarcomas. PubMed 40563544
- Cancer Sci, 2025 (senior author): PD-1 blockade treatment in melanoma: Mechanism of response and tumor-intrinsic resistance. PubMed 39601129
- Eur J Cancer, 2024 (senior author): The Role of CDCA2 in tumor genesis, prognosis and future treatments. PubMed 39288736
- Heliyon, 2024 (senior author): The combination of apatinib and antigen-specific DC-induced T cells exert antitumor effects by potently improving the immune microenvironment of osteosarcoma. PubMed 39224314
- Theranostics, 2024 (senior author): An advanced comprehensive muti-cell-type-specific model for predicting anti-PD-1 therapeutic effect in melanoma. PubMed 38505619
- Cancer Rep (Hoboken), 2023 (senior author): Prognostic value of the number of biopsied sentinel lymph nodes for Chinese patients with melanoma: A single-center retrospective study. PubMed 38148035
- J Surg Oncol, 2023 (senior author): Prediction of nonsentinel lymph node metastasis in acral melanoma with positive sentinel lymph nodes. PubMed 37689989
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion